No evidence for an increased GVHD risk associated with post-transplant Idelalisib given for relapse of chronic lymphocytic leukemia or lymphoma: First results of a survey by the EBMT chronic malignancy and lymphoma working parties

Author(s):: Dreger, P.; Boumendil, A.; Koster, L.; Scheid, C.; Passweg, J.; Veelken, H.; Cahn, Y.; Collin, M.; Wilson, K.; Bazarbachi, A.; Mayer, J.; Corradini, P.; Hunault-Berger, M.; Porras, R.P.; Gribben, J.; Bittenbring, J.; Wolff, D.; Charbonnier, A.; Cambier, N.; Montoto, S.; Kroger, N.; Schetelig, J.